We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.


13 January 2014 By Olaf Storbeck

U.S. drug wholesaler McKesson has failed to buy its German peer – despite both sides and most shareholders wanting a deal. The drawn-out process exposed weaknesses at Celesio and in Germany’s M&A rules. Elliott, the hedge fund that tried to play kingmaker, will suffer too.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)